First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743-Reference-Cited by-同舟云学术

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Published:2022-05 Issue:5 Volume:33 Page:488-499
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Peters S.,Scherpereel A.,Cornelissen R.,Oulkhouir Y.,Greillier L.,Kaplan M.A.,Talbot T.,Monnet I.,Hiret S.,Baas P.,Nowak A.K.,Fujimoto N.,Tsao A.S.,Mansfield A.S.,Popat S.,Zhang X.,Hu N.,Balli D.,Spires T.,Zalcman G.

Funder

Ono Pharmaceutical

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference45 articles.

1. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019

2. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial;Motzer;J Immunother Cancer,2020

3. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial;Motzer;Lancet Oncol,2019

4. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden;Hellmann;N Engl J Med,2018

5. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant pleural mesothelioma: The disdained member of thoracic oncology!;World Journal of Experimental Medicine;2024-09-20

2. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma;Lung Cancer;2024-09

3. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the “N” Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma;Journal of Thoracic Oncology;2024-09

4. Case report: complete response and long-term survival on third-line immunotherapy in patient with pleural mesothelioma;Frontiers in Oncology;2024-08-29

5. Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling;PharmacoEconomics;2024-08-23